MYRIAD CLINICAL PRESENTATIONS OF LUNG CANCER: A SINGLE CENTRE CROSS-SECTIONAL STUDY AT A TERTIARY CARE CENTRE IN WEST INDIA

GS Chowdhary, Kunal Kishore, Sharad Yadav

Abstract


Background:  Lung cancer is the leading cause of cancer death globally and is now considered as the commonest fatal malignancy in the developed world. India contributes to 20% of all deaths due to lung cancer in the world.

Methods: To study the clinical and paraneoplastic presentations of lung cancer, we carried out a single centre, cross sectional observational study on a cohort of 100 patients of freshly detected Lung cancer.

Results: Mean age of the subjects was 56.36 years and 30% of the cases were above 60 years of age. Majority (63%) of them were males and smokers (59%). Most common presenting symptoms were cough (22.21%), chest pain (16.13%), fever (14.37%), dyspnoea (11%) and hemoptysis (5.22%). Paraneoplastic syndromes comprised of anemia and leucopenia (20%) cases followed CNS manifestation (in 8%) cases. No association was observed between type of lung carcinoma and paraneoplastic syndrome.

Conclusion: Our study confirms the high prevalence of lung cancer in male smokers with predominantly respiratory complaints. Paraneoplastic  syndromes are not a rare entity in such patients and a high level of clinical suspicion is required for early detection of such cases.


Keywords


Lung cancer, anemia, paraneoplastic, smokers

Full Text:

PDF

References


T Sethi, Lung cancer Introduction, Review series, Thorax 2002;57:992–993

Khuri Fr, Herbst Rs, Fossells FV. Emerging therapies in non small-cell lung cancer. Ann Oncol 2001; 12: 739-44.

West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987–99.

Nath V, Grewal K S. Cancer in India. Ind J Med Res 1935; 23: 149- 190.

Thankappan KR & Thresia CU. Tobacco use & social status in Kerala. Indian J Med Res 2007; 126: 300-308 (http://www.icmr.nic.in/ijmr/2007/october/1007.pdf. Accessed on 26th November 2011.)

Pai SA. Gutka banned in Indian states. Lancet Oncol 2002; 3: 521.

Murray CJ & Lopez AD (Eds). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, Massachusetts: Harvard School of Public Health; 1996.

Jindal SK, Behera D. Clinical spectrum of primary lung cancer – review of Chandigarh experience of 10 years. Lung India 1990;8:94-98

Noronha V, Dikshit R, Raut N, Joshi A, Pramesh C S, George K, Agarwal J P, Munshi A, Prabhash K. Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience. Indian J Cancer 2012;49:74-8

Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Comparison of Aspects of Smoking Among Four Histologic Types of Lung Cancer. Tob Control 2008; 17(3): 198–204.

Khurana S. Lung cancer.

https://docs.google.com/viewer?a=v&q=cache:kcjOH8ZHPzMJ:sancd.org/upl oads/pdf/lungcancer-factsheet.

Tobacco Free Initiative (TFI). World Health Organization. http://www.who.int/tobacco/research/cancer/en/. Accessed on 26th November 2011.

Kirmani N, Jamil K, Naidu MUR. Occupational and environmental carcinogens in epidemiology of lung cancer in South Indian population. Biology and Medicine 2010; 2(4): 1-11.

Beckles AM, Spiro SG, Colice GL, Rudd RM. Initial evaluation of patients with lung cancer. Symptoms, signs, laboratory tests and paraneoplastic syndromes. Chest 2003; 123: 975

Sutherland G. Current approaches to the management of smoking cessation. Drugs 2002;62(Suppl 2):53–61

Anderson H A, Prakash UBS. Diagnosis of symptomatic lung cancer. Semin Respir Med 1982; 3:165.

Wilker J D, Fidias, P, Veikers, L, Perer, R P Malignancy related pericardial effusion. 127 cases from the Roswell Park cancer Institute. Cancer 1995; 76:1377

Alberg, AJ; MV; Samet, JM (2016). Chapter 52: Epidemiology of lung cancer.

Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379

World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008

Viswanathan R, Sen Gupta, Iyer PV. Incidence of primary lung cancer in India. Thorax. 1962;17:73–6.

GLOBOCAN 2012 report.

http://www.globocan.iarc.fr/old/summary_table_pop.html.asp?selection=89356&title=India&sex=0&type=0&window=1&sort=2&submit=%C2%A0 Execute .

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

Jindal SK, Behera D. Clinical spectrum of primary lung cancer – Review of Chandigarh experience of 10 years. Lung India. 1990;8:94–8.

Zhong L, Goldberg MS, Parent ME, Hanley JA. Exposure to environmental tobacco smoke and the risk of lung cancer: A meta-analysis. Lung Cancer. 2000;27:3–18.

Gupta D, Aggarwal A, Jindal S. Pulmonary effects of passive smoking: The Indian experience. Tob Induc Dis. 2002;1:129–36.

Krishnamurthy A, Vijayalakshmi R, Gadigi V, Ranganathan R, Sagar TG. The relevance of “nonsmoking-associated lung cancer” in India: A single-centre experience. Indian J Cancer. 2012;49:82–8.

Malik PS, Sharma MC, Mohanti BK, Shukla NK, Deo S, Mohan A, et al. Clinico-pathological profile of lung cancer at AIIMS: A changing paradigm in India. Asian Pac J Cancer Prev. 2013;14:489–94.

V Noronha1, R Dikshit2, N Raut3, A Joshi1, CS Pramesh4, K George4, JP Agarwal5, A Munshi5, K Prabhash1

Rawat J1, Girish S2, Sunil S3 et al. clinico, a pathological profile of the lung cancer in Uttrakhand. 2009

Alamoudi OS et al. aimed to assess the clinical, radiological, pathological, biochemical and bronchoscopic abnormalities in lung cancer patients

Baburao A et al. [3] aimed to evaluate the clinicpathological profile and haematological abnormalities associated with lung cancer in Bangalore, India.

Dubey N et al. [4] aimed to study the risk factors, the time taken to diagnose and the investigations useful in the diagnosis of lung cancer patients

Gupta R et al. [5] aimed to study the clinical features, radiological manifestations and histological types of primary lung carcinoma.

Hafez MR et al. [6] aimed to analyse the clinical, radiological, laboratory, and bronchoscopic findings characterizing each type of bronchogenic carcinoma.

Rana S et al. [7] aimed to study the clinical, radiological, and histopathological profile of endobronchial lesions detected during bronchoscopy.

Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328:1519.

Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323.

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.

Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013;119:3976-3983.

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018 Jul;68(4):297-316.

Wender R, Fontham E, Barrera E, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:106–117.

Neiderhuber JE, Armitage JO, Doroshow JA, Kastan MB, Tepper JE, eds. Cancer of the lung: non–small cell lung cancer and small cell lung cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Saunders; 2013.

Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med 2015; 139:469.

Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8:823.

Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:2078.

Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017; 376:2415.

Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med 2013; 159:411.

National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.

Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974; 65:299.

Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56:2107.

Athey VL, Walters SJ, Rogers TK. Symptoms at lung cancer diagnosis are associated with major differences in prognosis. Thorax 2018; 73:1177.

Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112:440.

Colice GL. Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT. Chest 1997; 111:877.

Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63:695.

Piehler JM, Pairolero PC, Gracey DR, Bernatz PE. Unexplained diaphragmatic paralysis: a harbinger of malignant disease? J Thorac Cardiovasc Surg 1982; 84:861.

Ramadan HH, Wax MK, Avery S. Outcome and changing cause of unilateral vocal cord paralysis. Otolaryngol Head Neck Surg 1998; 118:199.

Chen HC, Jen YM, Wang CH, et al. Etiology of vocal cord paralysis. ORL J Otorhinolaryngol Relat Spec 2007; 69:167.

Decker DA, Dines DE, Payne WS, et al. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Chest 1978; 74:640.

Maskell NA, Butland RJ, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003; 58 Suppl 2:ii8.

Swiderek J, Morcos S, Donthireddy V, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest 2010; 137:68.

Eren S, Karaman A, Okur A. The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT. Eur J Radiol 2006; 59:93.

Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax 1994; 49:14.

World Health Organization. Cancer. Fact Sheet No 297. January 2013.

Stenbygaard LE, Sørensen JB, Olsen JE. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung--a study from a cohort of 259 consecutive patients treated with chemotherapy. Acta Oncol 1997; 36:301.

Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28:483.

Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004; 44:317.

Oliver TW Jr, Bernardino ME, Miller JI, et al. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology 1984; 153:217.

Pagani JJ. Normal adrenal glands in small cell lung carcinoma: CT-guided biopsy. AJR Am J Roentgenol 1983; 140:949.

Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007; 242:882.

Doyle TJ. Brain metastasis in the natural history of small-cell lung cancer: 1972-1979. Cancer 1982; 50:752.

Hiraki A, Ueoka H, Takata I, et al. Hypercalcemia-leukocytosis syndrome associated with lung cancer. Lung Cancer 2004; 43:301.

Thomas L, Kwok Y, Edelman MJ. Management of paraneoplastic syndromes in lung cancer. Curr Treat Options Oncol 2004; 5:51.

List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1986; 4:1191.

Hansen O, Sørensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 2010; 68:111.

Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064.

Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2:22.

Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.

Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745.

Kosmidis P, Krzakowski M, ECAS Investigators. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer 2005; 50:401.

Kasuga I, Makino S, Kiyokawa H, et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001; 92:2399.

Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax 2005; 60:1059.

Aoe K, Hiraki A, Ueoka H, et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71:170.

Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004; 23:330.

Ost DE, Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e121S.

Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e142S.

Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e211S.

Mohammed N, Kestin LL, Grills IS, et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79:466.

Ford DW, Koch KA, Ray DE, Selecky PA. Palliative and end-of-life care in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e498S


Refbacks

  • There are currently no refbacks.